CorePharma Expands CDMO Capabilities With New Spray Drying Technology

COMPANY PROFILE
  • CorePharma has added a spray drying platform to support poorly soluble compounds from early feasibility studies through clinical supply, using Buchi and Yamato spray drying systems.
  • The platform uses closed-loop nitrogen operation to process organic solvent systems and enables development and clinical manufacturing to remain with a single CDMO partner.

CorePharma, a contract development and manufacturing organization (CDMO), has expanded its manufacturing capabilities with a spray drying platform designed to support poorly soluble compounds from early feasibility studies through clinical supply. The platform is intended to help pharmaceutical clients improve the solubility and bioavailability of challenging active pharmaceutical ingredients (APIs), particularly through amorphous solid dispersions (ASDs).

The new platform combines two spray drying systems to support different stages of development. A Buchi spray dryer will be used for early-stage feasibility studies, formulation screening and ASD development, particularly when API supplies are limited. A Yamato DL410 spray dryer will support pilot-scale operations and clinical manufacturing, providing a scale-up pathway for programs progressing toward clinical supply.

Both systems operate in a closed-loop nitrogen environment, allowing the safe processing of organic solvent systems. This gives formulation teams flexibility in selecting solvents based on the requirements of individual molecules.

By keeping development and clinical manufacturing with one CDMO partner, CorePharma aims to reduce technology transfer risks, shorten development timelines and support the safe handling of solvent-based formulations. CEO Arpit Patel said the platform provides continuity for clients as their molecules progress from initial development to clinical supply.

EXCLUSIVE DOWNLOAD

Download the full CDMO Live Report for 112 pages of insights and best practices in external manufacturing.